This phase III trial is comparing survival outcomes for patients with high-risk cutaneous squamous cell carcinoma who are treated with adjuvant immunotherapy (cemiplimab), compared to those who are treated with a placebo, after surgery and radiotherapy.
This trial is treating patients with cutaneous squamous cell carcinoma.
This is a systemic therapy trial.
You may be able to join this trial if:
- Your cancer has not spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma
Eligible participants will be randomised to receive intravenous cemiplimab or a placebo for a duration of 30 minutes. The primary objective of the trial will be to compare disease-free survival between the two arms of the study.
Recruiting Hospitals Read More